Arnaud Prigent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arnaud Prigent has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Frédéric Gagnadoux
Department of Respiratory and Sleep Medicine, Angers University hospital, Angers, France
6 shared publications - Jean-Louis Pépin
University Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France
6 shared publications - Dany Jaffuel
Groupe Adène, Montpellier, France
4 shared publications Régis Luraine
4 shared publications- Sébastien Bailly
Grenoble Alpes University, Inserm U1300, CHU Grenoble Alpes, HP2, Grenoble, France
4 shared publications Anne Josseran
ResMed Science center, Saint-Priest, France
3 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA2290
Cheyne stokes respiration tracked by PAP telemonitoring predicts mortality and cardiovascular events in OSA patients.
Background and Aims: Home telemonitoring of positive airway pressure (PAP) therapy could help identify patients at risk of incident cardiovascular (CV) events through the occurrence of Cheyne–Stokes respiration (CSR). This study aimed to assess whether CSR detected through long-term PAP telemonitoring is associated with an increased risk of mortality and cardiovascular morbidity. Methods: The study was conducted using data from the Pays de la Loire Sleep Cohort, linked to the French national administrative health database. Patients treated with a RESMED PAP device for moderate-to-severe OSA were included. The exposure was the first of occurrence of a mean weekly CSR ≥4% measured between January 1st 2023 and December 31th 2024. The primary outcome, major adverse CV events (MACE) was a composite of incident stroke, cardiac events, or all-cause mortality. A time-dependent Cox model was used for the primary objective and adjusted for major confounders, including PAP adherence and cardiovascular medication use. Results: Overall, 1,799 patients were included, (72% males; median [IQR] age, 56 [47; 64] years; BMI, 31 [27; 36] kg/m²; AHI, 38 [30; 54] events/h). PAP tele monitoring revealed mean weekly CSR ≥4% in 431 (24%) patients and 159 (9%) patients experienced a MACE during follow-up (2 years). Mean weekly CSR ≥4% was associated with an increased risk of MACE (adjusted hazard ratio [95% confidence interval]: 1.56 [1.09–2.24]; p=0.015). Similar results were observed in patients without a prior history of cardiovascular disease at inclusion (HR: 1.69 [1.01; 2.82], p=0.045). Conclusions: In this multicentre, sleep-clinic cohort, the first detection of a weekly mean CSR ≥4% on PAP tele monitoring was associated with a higher risk of MACE.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA2290
Cheyne stokes respiration tracked by PAP telemonitoring predicts mortality and cardiovascular events in OSA patients.
Background and Aims: Home telemonitoring of positive airway pressure (PAP) therapy could help identify patients at risk of incident cardiovascular (CV) events through the occurrence of Cheyne–Stokes respiration (CSR). This study aimed to assess whether CSR detected through long-term PAP telemonitoring is associated with an increased risk of mortality and cardiovascular morbidity. Methods: The study was conducted using data from the Pays de la Loire Sleep Cohort, linked to the French national administrative health database. Patients treated with a RESMED PAP device for moderate-to-severe OSA were included. The exposure was the first of occurrence of a mean weekly CSR ≥4% measured between January 1st 2023 and December 31th 2024. The primary outcome, major adverse CV events (MACE) was a composite of incident stroke, cardiac events, or all-cause mortality. A time-dependent Cox model was used for the primary objective and adjusted for major confounders, including PAP adherence and cardiovascular medication use. Results: Overall, 1,799 patients were included, (72% males; median [IQR] age, 56 [47; 64] years; BMI, 31 [27; 36] kg/m²; AHI, 38 [30; 54] events/h). PAP tele monitoring revealed mean weekly CSR ≥4% in 431 (24%) patients and 159 (9%) patients experienced a MACE during follow-up (2 years). Mean weekly CSR ≥4% was associated with an increased risk of MACE (adjusted hazard ratio [95% confidence interval]: 1.56 [1.09–2.24]; p=0.015). Similar results were observed in patients without a prior history of cardiovascular disease at inclusion (HR: 1.69 [1.01; 2.82], p=0.045). Conclusions: In this multicentre, sleep-clinic cohort, the first detection of a weekly mean CSR ≥4% on PAP tele monitoring was associated with a higher risk of MACE.
- Open Access
- 10 October 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003066
Unravelling telemonitoring data to predict good NIV quality: the E-QualiNIV study
Background and objective: High treatment quality, defined by mean adherence >4 hours per day, unintentional leaks <24 L/min and a residual Apnoea–Hypopnoea Index <5 events per hour, is associated with better outcomes. Adherence variance may reflect behaviour linked to better treatment quality. This study aimed to assess whether monthly adherence variance is associated with improved treatment quality in patients treated with non-invasive ventilation (NIV) for more than 4 months. Methods: E-QualiNIV is a retrospective study evaluating treatment quality in 511 telemonitored patients with chronic respiratory failure, observed from 15 April to 31 October 2023. The study followed three steps: (1) hierarchical clustering based on individual adherence variance; (2) assessing whether monthly adherence variance in the preceding month predicted the proportion of alerts in the subsequent month and (3) evaluating treatment quality based on the number of months with low adherence variance. Results: Cluster 1, consisting of patients with adherence variance below 3, had a significantly higher proportion (57.93%) of patients achieving high-quality treatment compared with other clusters (43.1% for cluster 2 and 46.4% for cluster 3) (p=0.035). Patients with a low adherence variance in the preceding month were more likely to achieve high-quality treatment in the following month (except for May, significant differences every month from p=0.04 to p<0.01). Those with 6 or more months of low adherence variance had a significantly higher probability of receiving high-quality treatment over the entire period (coefficient: 0.2649, p value: 0.0028) compared with those who did not (non-significant). Conclusion: The E-QualiNIV study demonstrates that low adherence variance is associated with high-quality treatment and serves as a prognostic indicator of treatment stability and alert occurrence in the subsequent month.
- 10 October 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003066
Open AccessUnravelling telemonitoring data to predict good NIV quality: the E-QualiNIV study
Background and objective: High treatment quality, defined by mean adherence >4 hours per day, unintentional leaks <24 L/min and a residual Apnoea–Hypopnoea Index <5 events per hour, is associated with better outcomes. Adherence variance may reflect behaviour linked to better treatment quality. This study aimed to assess whether monthly adherence variance is associated with improved treatment quality in patients treated with non-invasive ventilation (NIV) for more than 4 months. Methods: E-QualiNIV is a retrospective study evaluating treatment quality in 511 telemonitored patients with chronic respiratory failure, observed from 15 April to 31 October 2023. The study followed three steps: (1) hierarchical clustering based on individual adherence variance; (2) assessing whether monthly adherence variance in the preceding month predicted the proportion of alerts in the subsequent month and (3) evaluating treatment quality based on the number of months with low adherence variance. Results: Cluster 1, consisting of patients with adherence variance below 3, had a significantly higher proportion (57.93%) of patients achieving high-quality treatment compared with other clusters (43.1% for cluster 2 and 46.4% for cluster 3) (p=0.035). Patients with a low adherence variance in the preceding month were more likely to achieve high-quality treatment in the following month (except for May, significant differences every month from p=0.04 to p<0.01). Those with 6 or more months of low adherence variance had a significantly higher probability of receiving high-quality treatment over the entire period (coefficient: 0.2649, p value: 0.0028) compared with those who did not (non-significant). Conclusion: The E-QualiNIV study demonstrates that low adherence variance is associated with high-quality treatment and serves as a prognostic indicator of treatment stability and alert occurrence in the subsequent month.
- 1 October 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (10) , 1554-1566
Health Trajectories around Noninvasive Ventilation Initiation for Obesity Hypoventilation Syndrome
Rationale: Positive airway pressure therapy modalities in obesity hypoventilation syndrome (OHS) are still debated. Objectives: To describe health trajectories before and after starting noninvasive ventilation (NIV) and compare post-NIV outcomes between groups with different pre-NIV trajectories. Methods: Data came from the French national health insurance reimbursement database for individuals with OHS and one or more NIV prescriptions between January 1, 2015, and December 31, 2019. Health trajectory clusters were determined using mixture models that were graphically represented by time sequence analysis. Results: Data from 8,842 individuals were analyzed (59.7% had coexisting obstructive sleep apnea, 64% had one or more comorbidities). Median follow-up was 3.1 years. Cluster 1 (n = 5,853; 66.2%) started NIV while stable after pulmonary function testing, arterial blood gas (ABG) analysis, and sleep studies; 23.7% underwent bariatric surgery around NIV initiation. One-year therapy termination and mortality rates were 51.8% and 5.5%, respectively. Cluster 2 (n = 757; 8.6%) started NIV during or immediately after one or more acute intensive care unit hospitalizations in the previous year; 1-year NIV termination and mortality rates were 34.3% and 9.1%, respectively. Cluster 3 (n = 526; 5.9%) had NIV initiation after a sleep study, pulmonary function testing/arterial blood gas analysis, and approximately 3 months of continuous positive airway pressure; 1-year therapy termination and mortality rates were 23.0% and 2.1%, respectively. In cluster 4 (n = 1,706; 19.3%), long-term continuous positive airway pressure preceded the switch to NIV after reassessment in ambulatory care; 1-year therapy termination and mortality rates were 18.4% and 4.5%, respectively. Conclusions: These novel data highlight marked heterogeneity in OHS and use of positive airway pressure therapies, which significantly impacts outcomes.
- 1 October 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (10) , 1554-1566
Health Trajectories around Noninvasive Ventilation Initiation for Obesity Hypoventilation Syndrome
Rationale: Positive airway pressure therapy modalities in obesity hypoventilation syndrome (OHS) are still debated. Objectives: To describe health trajectories before and after starting noninvasive ventilation (NIV) and compare post-NIV outcomes between groups with different pre-NIV trajectories. Methods: Data came from the French national health insurance reimbursement database for individuals with OHS and one or more NIV prescriptions between January 1, 2015, and December 31, 2019. Health trajectory clusters were determined using mixture models that were graphically represented by time sequence analysis. Results: Data from 8,842 individuals were analyzed (59.7% had coexisting obstructive sleep apnea, 64% had one or more comorbidities). Median follow-up was 3.1 years. Cluster 1 (n = 5,853; 66.2%) started NIV while stable after pulmonary function testing, arterial blood gas (ABG) analysis, and sleep studies; 23.7% underwent bariatric surgery around NIV initiation. One-year therapy termination and mortality rates were 51.8% and 5.5%, respectively. Cluster 2 (n = 757; 8.6%) started NIV during or immediately after one or more acute intensive care unit hospitalizations in the previous year; 1-year NIV termination and mortality rates were 34.3% and 9.1%, respectively. Cluster 3 (n = 526; 5.9%) had NIV initiation after a sleep study, pulmonary function testing/arterial blood gas analysis, and approximately 3 months of continuous positive airway pressure; 1-year therapy termination and mortality rates were 23.0% and 2.1%, respectively. In cluster 4 (n = 1,706; 19.3%), long-term continuous positive airway pressure preceded the switch to NIV after reassessment in ambulatory care; 1-year therapy termination and mortality rates were 18.4% and 4.5%, respectively. Conclusions: These novel data highlight marked heterogeneity in OHS and use of positive airway pressure therapies, which significantly impacts outcomes.
- Open Access
- 11 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6424
Positive Airway Pressure-Related Aerophagia in Obstructive Sleep Apnea: Results from the InterfaceVent Real-Life Study
Background: Continuous positive airway pressure (CPAP) effectiveness can be compromised by adverse effects. Despite its potential impact on adherence and sleepiness, aerophagia remains under-recognized and poorly characterized. This ancillary analysis of the InterfaceVent study aimed to identify risk factors for aerophagia in a large real-life cohort of CPAP-treated patients and to assess its association with both CPAP adherence and sleepiness. Methods: InterfaceVent was a prospective, real-life, cross-sectional study. Adults treated for at least 3 months with CPAP were included. Patients self-reported mask-related side effects using visual analogue scales. Aerophagia was defined as a dichotomous outcome based on patient-reported symptoms and CPAP non-adherence as mean nightly usage p < 0.001). CPAP usage was significantly lower in the aerophagia group (median 6.37 vs. 6.75 h/day; p = 0.001), whereas non-adherence, did not significantly differ between groups (10.7% vs. 7.5%; p = 0.20). Conclusions: This ancillary analysis of the InterfaceVent study highlights the burden of aerophagia in CPAP-treated patients and identifies modifiable and non-modifiable risk factors. Better recognition and management of this under-reported side effect may improve CPAP adherence and patient comfort. Trial registration: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The first registration date is 23 December 2016.
- 11 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6424
Open AccessPositive Airway Pressure-Related Aerophagia in Obstructive Sleep Apnea: Results from the InterfaceVent Real-Life Study
Background: Continuous positive airway pressure (CPAP) effectiveness can be compromised by adverse effects. Despite its potential impact on adherence and sleepiness, aerophagia remains under-recognized and poorly characterized. This ancillary analysis of the InterfaceVent study aimed to identify risk factors for aerophagia in a large real-life cohort of CPAP-treated patients and to assess its association with both CPAP adherence and sleepiness. Methods: InterfaceVent was a prospective, real-life, cross-sectional study. Adults treated for at least 3 months with CPAP were included. Patients self-reported mask-related side effects using visual analogue scales. Aerophagia was defined as a dichotomous outcome based on patient-reported symptoms and CPAP non-adherence as mean nightly usage p < 0.001). CPAP usage was significantly lower in the aerophagia group (median 6.37 vs. 6.75 h/day; p = 0.001), whereas non-adherence, did not significantly differ between groups (10.7% vs. 7.5%; p = 0.20). Conclusions: This ancillary analysis of the InterfaceVent study highlights the burden of aerophagia in CPAP-treated patients and identifies modifiable and non-modifiable risk factors. Better recognition and management of this under-reported side effect may improve CPAP adherence and patient comfort. Trial registration: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The first registration date is 23 December 2016.
- Open Access
- 12 July 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 1-7
Concerns arising from the calculation of the apnea-hypopnea index during CPAP-telemonitoring of patients with obstructive sleep apnea
Continuous Positive Airway Pressure (CPAP) telemonitoring is increasingly important in managing obstructive sleep apnea (OSA). The Apnea-Hypopnea Index reported by CPAP devices (AHIflow) is used as a key indicator of treatment effectiveness. However, discrepancies in AHIflow calculation rules between manufacturers may affect clinical decision-making. No prior studies have investigated whether manufacturers’ choices to exclude certain apnea-hypopnea events from the AHIflow calculation may influence the number of patients presenting an AHIflow alert. The aim of this proof-of-concept study was not to compare the manufacturers with each other, but to evaluate, for each manufacturer, how the different possible ways of calculating AHIflow influence the percentage of alert cases. We conducted a retrospective analysis of 13,764 CPAP-treated OSA patients monitored on October 2, 2023. AHIflow calculations were evaluated according to manufacturer-specific rules. When possible, we assessed the impact of excluding central hypopneas, events during major leaks, and/or ramp periods on the percentage of patients crossing the consensual AHIflow alert threshold of ≥ 10 events/h. We identified significant disparities in AHIflow calculations between manufacturers, which lead to significant differences in the number of patients flagged as being in an alert state. Excluding central hypopneas reduced the number of alert cases by 50%, while excluding apneas/hypopneas during major leaks or ramp periods reduced alerts by 20%. Our proof-of-concept study highlights inconsistencies in AHIflow calculations among CPAP manufacturers, raising concerns about patient care. Establishing standardized AHIflow calculation criteria is essential to ensuring accurate monitoring and optimal patient safety.
- 12 July 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 1-7
Open AccessConcerns arising from the calculation of the apnea-hypopnea index during CPAP-telemonitoring of patients with obstructive sleep apnea
Continuous Positive Airway Pressure (CPAP) telemonitoring is increasingly important in managing obstructive sleep apnea (OSA). The Apnea-Hypopnea Index reported by CPAP devices (AHIflow) is used as a key indicator of treatment effectiveness. However, discrepancies in AHIflow calculation rules between manufacturers may affect clinical decision-making. No prior studies have investigated whether manufacturers’ choices to exclude certain apnea-hypopnea events from the AHIflow calculation may influence the number of patients presenting an AHIflow alert. The aim of this proof-of-concept study was not to compare the manufacturers with each other, but to evaluate, for each manufacturer, how the different possible ways of calculating AHIflow influence the percentage of alert cases. We conducted a retrospective analysis of 13,764 CPAP-treated OSA patients monitored on October 2, 2023. AHIflow calculations were evaluated according to manufacturer-specific rules. When possible, we assessed the impact of excluding central hypopneas, events during major leaks, and/or ramp periods on the percentage of patients crossing the consensual AHIflow alert threshold of ≥ 10 events/h. We identified significant disparities in AHIflow calculations between manufacturers, which lead to significant differences in the number of patients flagged as being in an alert state. Excluding central hypopneas reduced the number of alert cases by 50%, while excluding apneas/hypopneas during major leaks or ramp periods reduced alerts by 20%. Our proof-of-concept study highlights inconsistencies in AHIflow calculations among CPAP manufacturers, raising concerns about patient care. Establishing standardized AHIflow calculation criteria is essential to ensuring accurate monitoring and optimal patient safety.
- Open Access
Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models
Rationale Chronic obstructive pulmonary disease (COPD) is the most common indication for domiciliary non-invasive ventilation (NIV), but long-term outcomes data are limited. Objective This multistate model analysis estimated the impact of NIV therapy continuation versus cessation on transitions between three different disease states. Methods Model data came from the French national health insurance reimbursement system database for individuals aged ≥40 years with COPD and ≥1 NIV reimbursement in 2015–2019. Measurement and main results Data from 49 503 patients started on NIV were included (median age 70 years, 51.2% male, median 1 exacerbation in the previous year). There were 80 361 severe exacerbations and 18 125 deaths (including 7805 in severe exacerbation). In multistate models, NIV continuation was associated with a significant reduction in transition to death, from severe exacerbation (HR 0.84, 95% CI 0.79 to 0.91) and without exacerbation (HR 0.88, 95% CI 0.83 to 0.93). NIV continuation versus cessation had no significant effect on transition between without exacerbation to severe exacerbation (HR 0.98, 95% CI 0.95 to 1.00) but was significantly associated with slower transition from severe exacerbation to without exacerbation (HR 0.87, 95% CI 0.84 to 0.89). Conclusion This multistate model analysis found that the long-term use of domiciliary NIV was associated with a lower risk of transitions to death, but was not associated with a reduction in recovery time after severe exacerbation. These data highlight the potential mortality benefits of long-term domiciliary NIV in COPD and can be used as one piece of evidence to support evidence-based guideline recommendations.
Open AccessImpact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models
Rationale Chronic obstructive pulmonary disease (COPD) is the most common indication for domiciliary non-invasive ventilation (NIV), but long-term outcomes data are limited. Objective This multistate model analysis estimated the impact of NIV therapy continuation versus cessation on transitions between three different disease states. Methods Model data came from the French national health insurance reimbursement system database for individuals aged ≥40 years with COPD and ≥1 NIV reimbursement in 2015–2019. Measurement and main results Data from 49 503 patients started on NIV were included (median age 70 years, 51.2% male, median 1 exacerbation in the previous year). There were 80 361 severe exacerbations and 18 125 deaths (including 7805 in severe exacerbation). In multistate models, NIV continuation was associated with a significant reduction in transition to death, from severe exacerbation (HR 0.84, 95% CI 0.79 to 0.91) and without exacerbation (HR 0.88, 95% CI 0.83 to 0.93). NIV continuation versus cessation had no significant effect on transition between without exacerbation to severe exacerbation (HR 0.98, 95% CI 0.95 to 1.00) but was significantly associated with slower transition from severe exacerbation to without exacerbation (HR 0.87, 95% CI 0.84 to 0.89). Conclusion This multistate model analysis found that the long-term use of domiciliary NIV was associated with a lower risk of transitions to death, but was not associated with a reduction in recovery time after severe exacerbation. These data highlight the potential mortality benefits of long-term domiciliary NIV in COPD and can be used as one piece of evidence to support evidence-based guideline recommendations.
- Open Access
Real-world telemonitoring and remote support for home non-invasive ventilation to improve therapy effectiveness: the exploratory, multicentre randomised eVENT study
Rationale: Telemonitoring has shown benefits during the initiation of home non-invasive ventilation (NIV) but evidence is lacking regarding its use during follow-up. A French national telemonitoring programme incorporating remote support and therapeutic education is designed to improve patient pathways and reduce healthcare resource utilisation. This study investigated the impact of the telemonitoring programme versus usual follow-up on the effectiveness of home NIV.Methods: The prospective, multicentre, open-label eVENT trial enrolled adults recently started on home NIV. Participants were randomised to the telemonitoring or usual follow-up group. In the telemonitoring group, a CE-marked algorithm generated alerts based on teletransmitted ventilator data. Specialised nurses managed alerts and provided therapeutic education. The primary outcome was mean nocturnal transcutaneous carbon dioxide level (PtCO2) on NIV after 6 months.Results: 56 patients were randomised and 53 were analysed (telemonitoring: n=27, usual follow-up: n=26). At 6 months, mean PtCO2did not differ significantly between the telemonitoring and usual follow-up groups (42.1±6.1 vs 43.9±6.4 mm Hg; p=0.352) but mean room air partial arterial carbon dioxide pressure (PaCO2) was significantly lower in the telemonitoring versus usual follow-up group (41.7±6.8 vs 46.2±3.5 mm Hg; p=0.003). The proportion of participants without diurnal or nocturnal hypercapnia at 6 months was 82.6% with telemonitoring and 27.3% with usual follow-up (p2was similar with telemonitoring and usual follow-up, but PaCO2levels and the quality of ventilatory support were significantly better with telemonitoring.Trial registration number: NCT04615078.
Open AccessReal-world telemonitoring and remote support for home non-invasive ventilation to improve therapy effectiveness: the exploratory, multicentre randomised eVENT study
Rationale: Telemonitoring has shown benefits during the initiation of home non-invasive ventilation (NIV) but evidence is lacking regarding its use during follow-up. A French national telemonitoring programme incorporating remote support and therapeutic education is designed to improve patient pathways and reduce healthcare resource utilisation. This study investigated the impact of the telemonitoring programme versus usual follow-up on the effectiveness of home NIV.Methods: The prospective, multicentre, open-label eVENT trial enrolled adults recently started on home NIV. Participants were randomised to the telemonitoring or usual follow-up group. In the telemonitoring group, a CE-marked algorithm generated alerts based on teletransmitted ventilator data. Specialised nurses managed alerts and provided therapeutic education. The primary outcome was mean nocturnal transcutaneous carbon dioxide level (PtCO2) on NIV after 6 months.Results: 56 patients were randomised and 53 were analysed (telemonitoring: n=27, usual follow-up: n=26). At 6 months, mean PtCO2did not differ significantly between the telemonitoring and usual follow-up groups (42.1±6.1 vs 43.9±6.4 mm Hg; p=0.352) but mean room air partial arterial carbon dioxide pressure (PaCO2) was significantly lower in the telemonitoring versus usual follow-up group (41.7±6.8 vs 46.2±3.5 mm Hg; p=0.003). The proportion of participants without diurnal or nocturnal hypercapnia at 6 months was 82.6% with telemonitoring and 27.3% with usual follow-up (p2was similar with telemonitoring and usual follow-up, but PaCO2levels and the quality of ventilatory support were significantly better with telemonitoring.Trial registration number: NCT04615078.
- Open Access
- 20 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (2)
Relevance of telemonitoring algorithms for the management of home noninvasive ventilation
Background: The increasing number of patients requiring home noninvasive ventilation (HNIV) is a challenge for our healthcare system. Telemonitoring may be used to facilitate the management of HNIV patients. We aimed to assess the ability of telemonitoring algorithms to identify patients not adequately ventilated. Our secondary aim was to assess the consequences related to these algorithms, including costs.Methods: Eleven HNIV experts each provided an algorithm to identify patients with suboptimal ventilation. Each algorithm was tested using real-life data from a cohort of patients over a 90-day period.Inadequate HNIV was defined as the presence of at least one criterion amongst the following: uncontrolled hypoventilation, daily adherence 10/h.Results: One hundred patients were included in the cohort. According to our criteria, HNIV was considered as inadequate in 66 (66%) patients, without difference between underlying respiratory disease. Telemonitoring algorithms correctly classified patients in 65 [52–66] % of cases. They had a global sensitivity of 78 [37–95] %, a specificity of 40 [19–78] %, a positive predictive value of 72 [65–77] % and a negative predictive value of 45 [37–51] %.Applying telemonitoring algorithms resulted in 127 [84–238] alerts across the study population with a median cost increase of €2064 [952–6262].Conclusion: Telemonitoring algorithms have poor diagnostic performances in identifying inadequately ventilated patient. They increase workload for healthcare workers and costs.
- 20 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (2)
Open AccessRelevance of telemonitoring algorithms for the management of home noninvasive ventilation
Background: The increasing number of patients requiring home noninvasive ventilation (HNIV) is a challenge for our healthcare system. Telemonitoring may be used to facilitate the management of HNIV patients. We aimed to assess the ability of telemonitoring algorithms to identify patients not adequately ventilated. Our secondary aim was to assess the consequences related to these algorithms, including costs.Methods: Eleven HNIV experts each provided an algorithm to identify patients with suboptimal ventilation. Each algorithm was tested using real-life data from a cohort of patients over a 90-day period.Inadequate HNIV was defined as the presence of at least one criterion amongst the following: uncontrolled hypoventilation, daily adherence 10/h.Results: One hundred patients were included in the cohort. According to our criteria, HNIV was considered as inadequate in 66 (66%) patients, without difference between underlying respiratory disease. Telemonitoring algorithms correctly classified patients in 65 [52–66] % of cases. They had a global sensitivity of 78 [37–95] %, a specificity of 40 [19–78] %, a positive predictive value of 72 [65–77] % and a negative predictive value of 45 [37–51] %.Applying telemonitoring algorithms resulted in 127 [84–238] alerts across the study population with a median cost increase of €2064 [952–6262].Conclusion: Telemonitoring algorithms have poor diagnostic performances in identifying inadequately ventilated patient. They increase workload for healthcare workers and costs.
- 23 January 2025
- Published by Elsevier in Sleep Medicine
- Vol. 128, 22-28
The influence of atmospheric temperature on long-term CPAP-usage in patients with obstructive sleep apnea
- 23 January 2025
- Published by Elsevier in Sleep Medicine
- Vol. 128, 22-28
The influence of atmospheric temperature on long-term CPAP-usage in patients with obstructive sleep apnea